Molecular Imaging Translational Network
The Molecular Imaging Translational Network is Australia’s largest research infrastructure team in molecular imaging and radiopharmaceuticals, spanning 9 PET scanners and 9 radiochemistry labs across 10 National Imaging Facility (NIF) Partners nationwide.
This national network provides streamlined access to world-class infrastructure and expertise in translational imaging and radiopharmaceutical development. Through collaborative research, the network strengthens Australia’s capabilities in imaging science and directly contributes to national health and innovation priorities.
A key focus is on high-burden diseases such as cancer and dementia, where advanced imaging can drive earlier diagnosis, better treatment, and improved outcomes.
Governance
The Molecular Imaging Steering Committee ensures scientific and technical oversight, accountability toward activities’ progress, and that NIF’s commitments to the network are aligned with Australia’s research priorities and NIF’s strategy. The current chair is Professor Andrew Scott AM.
Major Activity Streams
Cancer and Oncology
The Molecular Imaging Translational Network is harmonising PET scanning procedures across participating sites in Australia, broadening support for a range of clinical trials and working toward enabling easier access to new cancer diagnostics and therapies for patients.
Coordinating partners: 
Radiopharmaceuticals and Radiochemistry
The network supports the rapidly growing field of nuclear medicine and theranostics – personalised approaches that combine diagnostic imaging with targeted radiotherapy. Working with research and industry, the network improves access to novel radiopharmaceuticals.
Coordinating partner: 
Neurology, Neuroscience and Dementia
The network helps researchers test emerging treatments for dementia by advancing scanning techniques and developing an improved, standardised scale for measuring Alzheimer’s disease progression across sites and studies.
Coordinating partner: 
Clinical Trials
Coordinating partner: 
Major Activity Streams
Cancer and Oncology
The Molecular Imaging Translational Network is harmonising PET scanning procedures across participating sites in Australia, broadening support for a range of clinical trials and working toward enabling easier access to new cancer diagnostics and therapies for patients.
Coordinating partners:
Neurology, Neuroscience and Dementia
The network helps researchers test emerging treatments for dementia by advancing scanning techniques and developing an improved, standardised scale for measuring Alzheimer’s disease progression across sites and studies.
Coordinating partner:
Radiopharmaceuticals and Radiochemistry
The network supports the rapidly growing field of nuclear medicine and theranostics – personalised approaches that combine diagnostic imaging with targeted radiotherapy. Working with research and industry, the network improves access to novel radiopharmaceuticals.
Coordinating partner:
Clinical Trials
Coordinating partner:
Network Partners
- Our Institution Partners contribute their expertise and infrastructure to network activities.
- Our National Research Partners connect us with user communities, engaging with expert clinicians for translational development, patient advocacy groups, and clinical trial groups.
Access the Network
NIF and the Molecular Imaging Translational Network are open access to research and industry. Program and project leaders, researchers, clinicians, and industry project leaders are welcome to contact us about accessing the network’s capabilities.
Facilities and Instruments
Radiochemistry
Contact Us
How can the Molecular Imaging Translational Network support your research? We look forward to talking with you about your project ideas.
You can send your ideas and questions to us via our contact form, or speak to a network coordinator:
- Rishma Vidyasagar (email Rishma)
- Peter Bugeia (email Peter)